Arbutus Biopharma Corp Logo

Arbutus Biopharma Corp

A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).

ABUS | US

Overview

Corporate Details

ISIN(s):
CA03879J1003 (+2 more)
LEI:
Country:
United States of America
Address:
701 VETERANS CIRCLE, 18974 WARMINSTER
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company focused on virology, with a primary mission to develop a functional cure for chronic hepatitis B virus (HBV) infection. The company's strategy centers on developing combination drug regimens that attack the virus through multiple, complementary mechanisms. This multi-pronged approach aims to suppress viral DNA replication, reduce viral antigens (specifically HBsAg), and boost the host's immune response. Its innovative virology portfolio is led by imdusiran, an RNAi therapeutic being investigated as a cornerstone therapy in its HBV clinical studies. Arbutus leverages a team with deep scientific and commercial expertise to advance its pipeline for conditions with significant unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Arbutus Biopharma Corp filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Arbutus Biopharma Corp

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Arbutus Biopharma Corp via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ViGenCell Inc. Logo
Developing T-cell immune therapies to treat cancer and other incurable diseases.
South Korea
308080
Viking Therapeutics, Inc. Logo
Biopharma developing novel therapies for metabolic and endocrine disorders like obesity and NASH.
United States of America
VKTX
Virbac Logo
Develops animal health pharma, vaccines & diagnostics for vets, farmers & pet owners globally.
France
FR000
Vir Biotechnology, Inc. Logo
Immunology company developing antibody therapies for serious infectious diseases and cancer.
United States of America
VIR
Viridian Therapeutics, Inc.\DE Logo
Develops antibody therapies for rare autoimmune diseases, primarily Thyroid Eye Disease (TED).
United States of America
VRDN
ViroGates A/S Logo
Develops suPAR diagnostic tests for inflammation risk assessment in acute care and longevity.
Denmark
VIRO
Vistagen Therapeutics, Inc. Logo
Biopharma firm developing intranasal therapies for anxiety, depression & neurological disorders.
United States of America
VTGN
Vistin Pharma Logo
A leading global producer of Metformin Hydrochloride for the global healthcare market.
Norway
VISTN
Vita 34 AG Logo
A cell bank storing umbilical cord stem cells as biological insurance for families' future health.
Germany
V3V
Vivani Medical, Inc. Logo
Develops long-term subdermal drug implants for chronic diseases like diabetes & weight management.
United States of America
VANI

Talk to a Data Expert

Have a question? We'll get back to you promptly.